SEPN (Septerna, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by SEPN officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-10 | Rajiv Patni | Chief Medical Officer | A | — | — |
| 2026-09-03 | Daniel D. Long | SVP, Drug Discovery | MIXED | — | — |
| 2026-08-14 | RA Capital Nexus Fund III, L.P. | Director | Sell | — | — |
| 2026-08-14 | Third Rock Ventures V, L.P. | 10%+ Owner | Sell | — | — |
| 2026-08-13 | Elizabeth Bhatt | President and COO | MIXED | — | — |
| 2026-08-05 | Daniel D. Long | SVP, Drug Discovery | MIXED | — | — |
| 2026-07-17 | Elizabeth Bhatt | President and COO | MIXED | — | — |
| 2026-07-02 | Daniel D. Long | SVP, Drug Discovery | MIXED | — | — |
| 2026-06-24 | Daniel D. Long | SVP, Drug Discovery | MIXED | — | — |
| 2026-06-16 | Samira Shaikhly | Chief People Officer | MIXED | — | — |
| 2026-06-03 | Samira Shaikhly | Chief People Officer | MIXED | — | — |
| 2026-05-28 | Samira Shaikhly | Chief People Officer | MIXED | — | — |
| 2026-04-17 | Elizabeth Bhatt | President and COO | MIXED | — | — |
| 2026-03-04 | Samira Shaikhly | Chief People Officer | MIXED | — | — |
| 2026-02-20 | Elizabeth Bhatt | President and COO | MIXED | — | — |
| 2026-02-10 | Gil M Labrucherie | Chief Financial Officer | A | — | — |
| 2026-02-10 | Jae B. Kim | Chief Medical Officer | A | — | — |
| 2026-02-10 | Jeffrey Finer | Chief Executive Officer | A | — | — |
| 2026-02-10 | Daniel D. Long | SVP, Drug Discovery | A | — | — |
| 2026-02-10 | Elizabeth Bhatt | President and COO | A | — | — |
| 2026-02-10 | Samira Shaikhly | Chief People Officer | A | — | — |
| 2026-02-10 | Mark Andrew Wilson | Chief Legal Officer | A | — | — |
| 2026-02-10 | Uwe Klein | SVP, Biological Sciences | A | — | — |
| 2025-11-13 | Daniel D. Long | SVP, Drug Discovery | Sell | — | — |
| 2025-09-29 | Keith Michael Gottesdiener | Director | A | — | — |
| 2025-08-19 | Uwe Klein | SVP, Biological Sciences | M | — | — |
| 2025-08-11 | Daniel D. Long | SVP, Drug Discovery | A | — | — |
| 2025-08-11 | Samira Shaikhly | Chief People Officer | A | — | — |
| 2025-08-11 | Jeffrey Finer | Chief Executive Officer | A | — | — |
| 2025-08-11 | Elizabeth Bhatt | President and COO | A | — | — |
| 2025-08-11 | Jae B. Kim | Chief Medical Officer | A | — | — |
| 2025-08-11 | Gil M Labrucherie | Chief Financial Officer | A | — | — |
| 2025-08-11 | Uwe Klein | SVP, Biological Sciences | A | — | — |
| 2025-06-20 | Jeffrey K Tong | Director | A | — | — |
| 2025-06-20 | Jake Simson | Director | A | — | — |
| 2025-06-20 | Alan Ezekowitz | Director | A | — | — |
| 2025-06-20 | Abraham Bassan | Director | A | — | — |
| 2025-06-20 | Shalini Sharp | Director | A | — | — |
| 2025-06-20 | RA CAPITAL MANAGEMENT, L.P. | Director | A | — | — |
| 2025-06-20 | Bernard Coulie | Director | A | — | — |
| 2025-04-04 | Jeffrey Finer | CEO and President | M | — | — |
| 2025-03-10 | Alan Ezekowitz | Director | Buy | — | — |
| 2025-03-06 | Alan Ezekowitz | Director | Buy | — | — |
| 2025-02-27 | Gil M Labrucherie | Chief Financial Officer | Buy | — | — |
| 2025-02-27 | Jeffrey Finer | CEO and President | Buy | — | — |
| 2025-02-26 | Third Rock Ventures V, L.P. | 10%+ Owner | Buy | — | — |
| 2025-02-24 | Third Rock Ventures V, L.P. | 10%+ Owner | Buy | — | — |
| 2025-02-21 | Gil M Labrucherie | Chief Financial Officer | Buy | — | — |
| 2025-02-07 | Gil M Labrucherie | Chief Financial Officer | A | — | — |
| 2024-10-30 | Peter Kolchinsky | Director | MIXED | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 10,280,050 | — |
| — | Director | 5,523,915 | — |
| — | Chief Executive Officer | 821,907 | — |
| — | Director | 725,443 | — |
| — | President and COO | 192,890 | — |
| — | SVP, Biological Sciences | 127,533 | — |
| — | Director | 117,420 | — |
| — | SVP, Drug Discovery | 99,745 | — |
| — | Chief Financial Officer | 40,000 | — |
| — | Chief People Officer | 793 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the SEPN quote page; the site-wide leaderboard is on the insider transactions hub.